Last Updated : April 24, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | avapritinib | Advanced Systemic Mastocytosis | Received | |||
| TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Received | |||
| Alecensaro | alectinib | ALK-positive NSCLC | Received | |||
| Adcetris | Brentuximab vedotin | Hodgkin lymphoma | Received | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Received | |||
| TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Received | |||
| TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
| TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
| TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
| Keytruda | pembrolizumab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active |
Last Updated : April 24, 2024